Metabolism and excretion of an oral taxane analog, [ 14c]3'-tert- butyl-3'-n-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-a/- debenzoyl-4-o-methoxy-paclitaxel (bms-275183), in rats and dogs

Drug Metabolism and Disposition

Volumn 37, Issue 5, 2009, Pages 1115-1128

  Ly, Van T ^a   Caceres Cortes, Janet ^a   Zhang, Donglu ^a   Humphreys, W Griffith ^a   Ekhato, Ihoezo V ^a   Everett, Donald ^a   Comezogiu, S Nilgun ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' TERT BUTYL 3' N TERT BUTYLOXYCARBONYL 4 DEACETYL 3' N DEBENZOYL 3' DEPHENYL 4 O METHOXYCARBONYLPACLITAXEL; 3' TERT BUTYL 3' N TERT BUTYLOXYCARBONYL 4 DEACETYL 3' N DEBENZOYL 3' DEPHENYL 4 O METHOXYCARBONYLPACLITAXEL C 14; CARBON 14; DRUG METABOLITE; RADIOPHARMACEUTICAL AGENT; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; DRUG URINE LEVEL; FECES ANALYSIS; ION PAIR CHROMATOGRAPHY; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RADIOACTIVITY; RADIOCHROMATOGRAPHY; RAT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOTRANSFORMATION; BRIDGED COMPOUNDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; FECES; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; RATS; SPECIES SPECIFICITY;

CANIS FAMILIARIS; RATTUS;

EID: 66449127635     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.025809     Document Type: Article

References (33)

1. 14C with stable isotopes in drug metabolism studies. Drug Metab Dispos 24:697-701.
2. Anderson CD, Wang J, Kumar GN, McMillan JM, Walle UK, and Walle T (1995) Dexameth- asone induction of Taxol metabolism in rat. Drug Metab Dispos 23:1286-1290.
3. Baillie TA, Halpin RA, Matuszewski BK, Geer LA, Chavez-Eng CM, Dean D, Braun M, Doss G, Jones A, Marks T, et al. (2001) Mechanistic studies on the reversible metabolism of rofecoxib to 5-hydroxyrofecoxib in the rat: evidence for transient ring opening of a substituted 2-furanone derivative using stable isotope labeling techniques. Drug Metab Dispos 29:1614-1628.
4. Baillie TA and Rettenmeier AW (1986) Drug biotransformation: mechanistic studies with stable isotopes. J Clin Pharmacol 26:448-451.
5. Bardelmeijer HA, Roelofs AB, Hillebrand MJ, Beijnen JH, Schellens JH, and van Tellingen O (2005) Metabolism of docetaxel in mice. Cancer Chemother Pharmacol 56:299-306.
6. Bissery MC, Nohynek G, Sanderink GJ, and Lavelle F (1995) Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs 6:339-355, 363-368.
7. Broker LE, Veltkamp SA, Heath EI, Kuenen BC, Gall H, Astier L, Parker S, Kayitalire L, Lorusso PM, Schellens JH, et al. (2007) A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183. Clin Cancer Res 13:3906-3912.
8. BrowneTR(1986)Stable isotopesinpharmacologystudies: present and future. J Clin Phamacol 26:485-489.
9. Clarke SJ and Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36:99-114.
10. Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, Vieira I, and Wright M (1994) Taxolmetabolism by human liver microsomes: identification of cytochrome P450 isozymes involvedin its biotransformation. Cancer Res 54:386-391.
11. Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P, and Gueritte F (2002) Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos 30:438-445.
12. Gut I, Ojima I, Vaclavikova R, Simek P, Horsky S, Linhart I, Soucek P, Kondrova E, Kuznetsova LV, and Chen J (2006) Metabolism of new-generation taxanes in human, pig, minipig and rat liver microsomes. Xenobiotica 36:772-792.
13. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
14. Lim HK, Chen J, Cook K, Sensenhauser C, Silva J, and Evans DC (2008) A generic method to detect electrophilic intermediates using isotopic pattern triggered data-dependent high-resolution mass spectrometry. Rapid Commun Mass Spectrom 22:1295-1311.
15. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, and Rahmani R (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A family inhumans. Cancer Res 56:1296-1302.
16. Mastalerz H, Cook D, Fairchild CR, Hansel S, Johnson W, Kadow JF, Long BH, Rose WC,Tarrant J, Wu MJ, et al. (2003) The discovery of BMS-275183: an orally efficacious novel taxane. Bioorg Med Chem 11:4315-4323.
17. Monegier B, Gaillard C, Sable S, and Vuilhorgne M (1994) Structures of the major human metabolites of docetaxel (RP 56976 Taxotere). Tetrahedron Lett 35:3715-3718.
18. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, and Harris JW (1994) Selective biotransfor-mation of Taxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546.
19. Ringel I and Horwitz SB (1987) Taxol is converted to 7-epitaxol, a biologically active isomer,in cell culture medium. J Pharmacol Exp Ther 242:692-698.
20. Rose WC, Long BH, Fairchild CR, Lee FY, and Kadow JF (2001) Preclinical pharmacology of BMS-275183, an orally active taxane. Clin Cancer Res 7:2016-2021.
21. Rowinsky EK and Donehower RC (1995) Paclitaxel. N Engl J Med 332:1004-1014.
22. Royer I, Monsarrat B, Sonnier M, Wright M, and Cresteil T (1996) Metabolism of docetaxel by human cytochrome P450 interactions with paclitaxel and other antineoplastic drugs. CancerRes 56:58-65.
23. Saville MW, Lietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, Humphrey RW, Feigal E,Steinberg SM, Broder S, et al. (1995) Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 346:26 -28.
24. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, and Gelboin HV (1998) Role of human cytochrome P450 3A4 and 3A5 in the metabolism of Taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8:391-401.
25. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, and van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035.
26. Sparreboom A, van Tellingen O, Nooijen WJ, and Beijnen JH (1998) Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 9:1-17.
27. Tong W, Chowdhury SK, Su AD, Feng W, Ghosal A, and Alton KB (2006) Identification of unstable metabolites of Lonafarnib using liquid chromatography-quadrupole time-of-flight mass spectrometry, stable isotope incorporation and ion source temperature alteration. J Mass Spectrom 41:1430-1441.
28. VandenHeuvel WJ (1986) Drug metabolite identification: stable isotope methods. J Clin Pharmacol 26:427-434.
29. van Oosterom AT, Schrijvers D, and Schriivers D [corrected to Schrijvers D] (1995) Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: clinical experience. Anticancer Drugs 6:356-368.
30. Wall ME and Wani MC (1995) Camptothecin and Taxol: discovery to clinic-thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 55:753-760.
31. Wani MC, TaylorHL, Wall ME, Coggon P, and McPhail AT (1971) Plant antitumoragents. VI.The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325-2327.
32. Zhang D, Ly V, Lago M, Tian Y, Gan J, Humphreys WG, and Comezoglu SN (2009) CYP3A4-mediated ester cleavage as the major metabolic pathway of the oral taxane 3'-tert- butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl- 3'-N-debenzoyl-4-O-methoxy-paclitaxel (BMS-275183). Drug Metab Dispos 37:710-718.
33. Zhang JW, Ge GB, Liu Y, Wang LM, Liu XB, Zhang YY, Li W, He YQ, Wang ZT, Sun J, et al. (2008) Taxane's substituents at C3' affect its regioselective metabolism: different in vitro metabolism of cephalomannine and paclitaxel. Drug Metab Dispos 36:418-426.